Related by context. All words. (Click for frequent words.) 60 Asthma Intervention 59 Laryngeal Cancer 59 RE LY 59 ImmunoCAP ® 59 Schizophrenia Treatment 59 Carotid Revascularization Endarterectomy vs. 59 Phase Ib clinical 59 Myocardial Perfusion Imaging 59 STRIDE PD 58 Patient Satisfaction Survey 58 Clinical Outcome 58 phase IIIb 58 Acute Decompensated Heart Failure 58 Clinical Guideline 58 BARI 2D 57 CAMMS# 57 multicenter Phase 57 Prospective Randomized 57 prospective multicentre 57 somo • v 57 Adverse Event 57 Coronary Revascularization 57 Diabetes Complications 57 Orqis Medical 57 Stent Thrombosis 57 SF #v# 57 transcranial Doppler ultrasound 57 LUX Lung 57 Phase #/#a 57 HCV SPRINT 56 BRIM2 56 Risk Stratification 56 Appropriateness Criteria 56 Analyte 56 CHAMPION PCI 56 PCI ExTRACT TIMI 56 Sleep Disturbance 56 randomized controlled Phase 56 Patient Registry 56 CT Angiography 56 PRE SURGE 56 ADMIRE HF 56 Comparative Biometric Testing 56 GRAVITAS trial 56 TAXUS ATLAS 56 BRIM3 56 AIR2 Trial 56 Echocardiographic 56 Phase Ib II 56 Ellex 2RT 56 Cardiac Imaging 56 Randomized Evaluation 56 NO# [002] 55 Acute Ischemic Stroke 55 phase IIb study 55 Optical Coherence Tomography 55 Diabetic Foot Ulcer 55 ENESTnd 55 multicenter phase 55 NABTT 55 Blood Pressure Monitoring 55 Vertebral Fracture 55 Cardiotoxicity 55 Demonstrates Sustained 55 Inflammatory Arthritis 55 RE MODEL 55 multicenter randomized clinical 55 exploratory endpoints 55 ORACLE MS 55 Evaluation Process 55 Angiographic 55 Clinical Evaluation 55 PRoFESS 55 Test Methodology 55 Labguard ™ 55 Arterial Hypertension 55 VADT 55 Women Ischemia Syndrome 55 ENGAGE AF TIMI 55 Current Controlled Trials 55 APEX AMI trial 55 formal pharmacokinetic PK 55 Respiratory Virus 55 ACCF AHA 55 Clinical Practice Guideline 55 BCIRG 55 Clinical Antipsychotic Trials 55 multicenter randomized controlled 55 randomized Phase IIb 55 Clinical Significance 55 Tumor Response 54 Phase IIIb 54 Randomized Clinical Trial 54 ECASS 54 OBPM 54 Phase Ib study 54 Lung Injury 54 Anticoagulation 54 PRECiSE 54 phase IIa clinical 54 Horizon Scanning 54 Acute Stroke 54 See CLINICAL PHARMACOLOGY 54 Multicenter 54 PROSTVAC ® 54 Nicotine Vaccine 54 Phase IIB 54 Adult Cardiac Surgery 54 Multicenter Phase 54 ENDEAVOR IV 54 blinded randomized placebo controlled 54 GAMMAGARD 54 multicentre randomized 54 Cardiovascular Risk Reduction 54 Resurgex Plus 54 HuMax HepC 54 Patient Outcomes 54 CLIRS 54 Patency 54 Eur Urol 54 Formative Assessment 54 phase IIa 54 Investigator Initiated 54 Aggressive Reduction 54 Data Extraction 54 Quinamed 54 ADVANCE PD 54 Carotid Artery Stenting 54 Antimicrobial Coating 54 OLYMPIA registry 54 Guideline Update 54 HuMax EGFr 54 Degarelix 54 Platelet Function 54 HORIZONS AMI trial 54 Coronary Artery Bypass Graft 54 Ambulatory EHR ensures 54 LUMINATE 54 Clinical Decision Making 54 Functional Capacity 53 AIR CF2 53 placebo controlled clinical 53 multicentre prospective 53 pharmacokinetic PK study 53 Intervention Effectiveness 53 Randomized Double blind 53 Treatment Outcome 53 ENDEAVOR II 53 Multicenter Trial 53 RE LY ® 53 Adjuvant Breast Cancer 53 ATAC Arimidex Tamoxifen Alone 53 fosbretabulin 53 HCV RESPOND 2 53 Cholesterol Levels SPARCL 53 acyclovir Lauriad R 53 Dialysis Outcomes 53 NSABP B 53 phase Ib 53 REVIVE Diabetes 53 Female Urology 53 AVERROES 53 Cytometry 53 placebo controlled Phase 53 Phase 2b study 53 Inhaled Nitric Oxide 53 Hematological 53 AIR CF3 53 AIR CF1 53 Relieve Depression 53 Surgical Ablation 53 Gastric Cancer 53 subanalysis 53 MelaFind pivotal 53 NCIC CTG 53 MEND CABG 53 Percutaneous Tibial Nerve Stimulation 53 prospective multicenter 53 Controlled Study 53 Phase IIA 53 longitudinal observational study 53 Screening Trial 53 Natural Catastrophe Stress 53 Clinical Practice Guidelines 53 SAFENANO 53 basal bolus regimen 53 treatment naive genotype 53 MediServe 53 Study Validates 53 Efficacy Study 53 Response Evaluation Criteria 53 Process Validation 53 Randomized Controlled Trials 53 Stenting Trial CREST 53 bronchial thermoplasty 53 ROCKET AF 53 multicenter Phase II 53 ACCORD Eye 53 EBMT criteria 53 APPRAISE 52 ProUroScan 52 randomized multicenter 52 efficacy endpoint 52 Bioequivalence 52 GISSI 52 Assessment Methodology 52 SUCCEED trial 52 Minimally Invasive Surgical 52 Pregnancy Outcomes 52 Left Ventricular Dysfunction 52 longitudinal cohort study 52 Heart Failure Therapy 52 phase IIb trial 52 Emphasys 52 phase IIb 52 Ischemic Stroke 52 Phase IIIb study 52 pharmacokinetic PK 52 pivotal bioequivalence 52 EVEREST II 52 Immunogenicity 52 Intensive Care Medicine 52 Refractory Angina 52 QUASAR validation study 52 label multicenter Phase 52 Phase 1a clinical 52 STEP BD 52 Practice Guideline 52 Stenting Trial 52 Coronary Angiography 52 Testing Methodology 52 Randomized Clinical Trials 52 Aggressive Drug Evaluation 52 prospective randomized multicenter 52 TQT 52 SIMPADICO 52 APTIVUS 52 Percutaneous Coronary Interventions 52 morphometric vertebral fractures 52 placebo controlled multicenter 52 Lifestyle Intervention 52 Placebo Controlled Trial 52 Platelet Inhibition 52 Safe Medication 52 Biological Effects 52 Thrombolysis 52 cinacalcet 52 Immunohistochemistry 52 Oral NKTR 52 Endovascular System 52 Guidance Document 52 MEND CABG II 52 Wechsler Adult 52 prospective multicenter randomized 52 Feasibility Trial 52 DFSS 52 Fracture Intervention Trial 52 CALGB 52 SPIRIT FIRST 52 MERLIN TIMI 52 randomized multicenter trial 52 PICSO ® 52 PRIALT 52 NATRECOR R 52 Serious Adverse Events 52 OneForce 52 FOR AN OPEN 52 Adult Stem Cell Therapy 52 NeuroStar TMS Therapy 52 Improving Patient Safety 52 Sipuleucel T 52 Myocardial Ischemia 52 EORTC 52 k Rekon 52 brivaracetam 52 dose escalation clinical 52 bevirimat Study 52 Immunomedics Announces 52 Neuroanatomy 52 Randomized Study 52 Intervention Trial 52 ICON7 52 Randomised 52 Bayer HealthCare Onyx Pharmaceuticals 52 Chronic Heart Failure 52 Renal Transplant 52 multicenter clinical 52 clevidipine 52 biostatistical analysis 52 Vasotrac 52 Phase 1b clinical 52 MetaVision Suite 52 NICE SUGAR 52 UA NSTEMI 52 preclinical efficacy 52 Denufosol 52 relapsing multiple sclerosis 52 Pharmacokinetic parameters 52 Phase 1b trial 52 Diagnostic Criteria 52 Thorough QT 52 Acute Myocardial Infarction 52 somatostatin analog 52 Carotid Endarterectomy 52 NCCN Oncology 52 Clinical Outcomes Utilizing Revascularization 52 observational cohort study 52 Severe Asthma 52 Assessment Questionnaire 52 multicenter prospective 52 Epilepsy Surgery 52 DAPT 52 Pharmacoeconomic 52 PRESEPT Study 51 Molecular Pathogenesis 51 Lupus Drug 51 CAMPATH 51 ACS NSQIP 51 Hemodialysis Patients 51 Tuberculosis Vaccine 51 GOUT 51 Meta Analysis 51 Stimulation Therapy 51 OPTIMIZE 51 aldosterone antagonists 51 Total Knee Arthroplasty 51 Quality Indicators 51 Investigational Drugs 51 Complications Trial 51 Cardiac Allograft Rejection 51 mg BID dose 51 CBC EVAL 51 Management Maturity Model 51 Opioid Use 51 Shows Efficacy 51 AA Amyloidosis 51 VIRAMUNE XR 51 Blood Pressure Measurement 51 Enzastaurin 51 DEFINITIVE AR 51 Clinical Efficacy 51 Renal Cancer 51 Stent Placement 51 PD2i R 51 BreastCancer 51 ADHERE 51 ASCO Gastrointestinal Cancers Symposium 51 icatibant 51 BENICAR HCT 51 Oral Fluid 51 prospective multicenter study 51 Patellofemoral 51 prucalopride 51 Endovascular Valve Edge 51 Vendor Selection 51 Acute Coronary Syndromes ACS 51 Peripheral Arterial 51 6S System 51 NIST Smart Grid 51 Main Outcome Measure 51 Molecular Basis 51 Glybera R 51 Crit Line 51 Cervical Spine 51 TMC# C# 51 Patient Oriented 51 Metabolic Disorder 51 Arch Intern Med 51 intermittent dosing 51 dose escalation Phase 51 Sociodemographic 51 II Clinical Trial 51 Myocardial Perfusion 51 Phase 2a clinical 51 Smallpox Vaccination Program 51 RNAi Therapeutic 51 Antiviral Therapy 51 Uterine Cancer 51 Glufosfamide 51 SYNTAX 51 Circulating Tumor Cell 51 FlexStent ® 51 Breast Density 51 PDx 51 duplex ultrasonography 51 MYTHOS trial 51 multicenter placebo controlled 51 Digital Mammographic Imaging 51 WEICan 51 XPEL Announces 51 ONTARGET 51 atherosclerotic renal artery stenosis 51 Antibacterial Drug 51 Phase III metastatic melanoma 51 number NCT# ClinicalTrials.gov 51 Therapeutic Intervention 51 Lung Cancer Screening 51 IMPACT DCM 51 Western Airborne Contaminants 51 UroVysion 51 CIMZIA TM 51 ACTEMRA TM 51 Solorel 51 Bionate ® PCU 51 AVONEX PEN 51 secondary efficacy endpoints 51 Antidepressant Treatment 51 Outcome Measures 51 Prostate Px + 51 prospective observational cohort 51 Spirus 51 HDL Selective Delipidation 51 transcatheter aortic valve implantation 51 Molecular Genetic 51 Endocrine Practice 51 Neuroendocrine Tumors 51 IRBS 51 Enters Beta 51 EMPHASIS HF 51 FDG-PET/CT 51 Screening Trial DMIST 51 LIALDA 51 Systemic Therapy 51 assessing T DM1 51 Hepatitis C Infection 51 ADAGIO study 51 PREVU * 51 Lucanix 51 Metametrix 51 Observational Study 51 ICAEL 51 neoadjuvant treatment 51 #F FDG PET 51 Nonalcoholic Fatty Liver Disease 51 Differential Diagnosis 51 Improve Diagnosis 51 Dr. Beilharz 51 Virtual Histology 51 Systematic Treatment 51 Spine Patient Outcomes 51 prospective longitudinal 51 randomized discontinuation 51 MoxDuo TM IR 51 Augment Injectable 51 Analytical Method 51 Bone Metabolism 51 Solid Tumors RECIST 51 prospective nonrandomized 51 CORD II 51 Edge STudy 51 Prostate Screening 51 Molecular Mechanism 51 Ovarian PLCO Cancer 51 MAQC 51 Fragment Library 51 CRLX# 51 Ischemic Events 51 AVADO 51 PRESEPT 51 Specification PAS 51 Scandinavian Simvastatin Survival 51 prospective observational 50 initiate multicenter 50 Vapor Intrusion 50 REVIVE TA 50 www.sanbolic.com 50 RECIST Response Evaluation Criteria 50 Common Criteria Evaluation 50 ExTRACT TIMI 50 ruboxistaurin 50 Venous Thromboembolism 50 Colposcopy 50 novel oral anticoagulant 50 Colorectal Screening 50 Surviving Sepsis Campaign 50 ARIXTRA 50 transesophageal echocardiography TEE 50 Schizophrenia Bulletin 50 Hydroxyurea 50 Multicenter Study 50 NSQIP 50 EMPHASIS HF trial 50 Decompensated Heart Failure 50 CLARITY TIMI 50 PFO migraine 50 cathepsin K inhibitor 50 Endarterectomy 50 ABSORB trial 50 Randomized controlled 50 riociguat 50 Physical Exams 50 transthoracic echocardiography 50 Cardiovascular Imaging 50 Renal Transplantation 50 Vicor PD2i 50 Am J Epidemiol 50 Hospitalized Patients 50 CT Scanning 50 Ranolazine 50 PERSEUS 50 Phase III placebo controlled 50 Acute Liver Failure 50 teriflunomide 50 MISRA 50 LungAlert TM 50 TRITON TIMI 50 Anti Inflammatory Drug 50 multicentre randomized double 50 Intervention Trial GAIT 50 ACCLAIM II 50 EchoCRT 50 Capacity FVC 50 randomized blinded 50 RECORD1 50 MBTI ® 50 CUSTOM III 50 percutaneous vertebroplasty 50 genomic biomarker 50 Prehospital Emergency Care 50 ZACTIMA 50 confirmatory clinical 50 Hepatitis C Treatment 50 Molecular Diagnostic 50 Skin sterol 50 Subgroup analysis 50 Diasome 50 multivariate Cox 50 Lung Cancer Detection 50 Capacity Optimization 50 Long Term Efficacy 50 Medtronic CareLink Network 50 Acute MI 50 Meta analyzes 50 Regression Analysis 50 BACcel 50 endothelin antagonists 50 J Foot Ankle 50 Sequenom SEQureDx Technology 50 CygnaCom 50 Wafer Bonding 50 Percutaneous Coronary Intervention 50 Adaptive Radiation Therapy 50 Confirms Efficacy 50 TM Embolic Protection 50 TB Vaccine 50 Confirmatory 50 Diagnostic Tests 50 Antiplatelet Therapy 50 Better Outcomes 50 CaPSURE 50 desvenlafaxine succinate 50 V3D 50 Phase 2a trial 50 Reduces Mortality 50 Authorized Generics 50 Combunox 50 pretreatment serum 50 Endoluminal 50 OvPlex ™ 50 pharmacokinetics PK 50 Pharmacodynamic 50 ARB telmisartan 50 Injury Mortality 50 Smallpox Vaccination 50 Tomographic 50 PD2i ® 50 hyperoxaluria 50 Mantoux test 50 SABCS 50 PRINCE2 ™ 50 Bare Metal Stent 50 Treating Chronic 50 Controlled Trial 50 CAM# 50 Pandemic Influenza Vaccines 50 multicenter randomized placebo controlled 50 ATACAND 50 SWOG 50 Pharmacokinetic PK 50 Quantitative Impact 50 Gastrointestinal Cancers Symposium 50 Spatio Temporal 50 Sustained Efficacy 50 Abciximab 50 Prospective Multicenter 50 Bio Nano Sensium 50 Adjuvant Therapy 50 FDA Investigational Device 50 iSIGHT 50 CLARITY study 50 MADIT CRT trial 50 recurrent malignant glioma 50 ALSYMPCA 50 Acute Kidney 50 randomized Phase 2b 50 EKC Cide 50 Assess ment 50 Prognostic Factors 50 AZOR 50 Cardiopulmonary bypass 50 Compliancy Software 50 ACUITY trial 50 phase 2a 50 DynoChem 50 Study Reinforces 50 Radiation Therapy Oncology 50 Primary endpoints 50 HIMSS# Interoperability Showcase 50 Ionizing Radiation 50 Freeze Drying 50 prospective randomized controlled 50 QL Care Analyzer 50 Clinical Outcomes 50 ImmuKnow assay 50 eNO 50 pharmacodynamic PD 50 Suicidality 50 Perinatal Mortality 50 GeneSightRx 50 Phase Ib 50 CIMZIA TM certolizumab pegol 50 Sorafenib HCC Assessment 50 Parasoft AEP Methodology 50 Rosuvastatin 50 Quadrivalent 50 Urocortin 2 50 Psychosocial Factors 50 ENVISION 50 enzyme immunoassay EIA 50 LAS# [002] 50 MADIT 50 Referenced EEG 50 NLX P# 50 Phase 2b randomized 50 CARE HF 50 Phase 2b trial 50 Phase IIa clinical 50 virological response 50 #.#ap 50 Cystatin C 50 oral FTY# 50 Common Toxicity Criteria 50 BENICAR 50 chemoradiotherapy 50 Governance Risk Compliance 50 Chronic Obstructive Lung 49 Regenerative Braking 49 Ocular Hypertension Treatment 49 buildingSMART alliance 49 directed thrombolysis 49 Kaplan Meier analysis 49 Cenzic Hailstorm 49 ToGA 49 Cognitive Abilities 49 PROactive study 49 bepotastine besilate nasal spray 49 Ovarian Cancer Screening 49 ChinaBio ® 49 Home Hemodialysis 49 Workplace Productivity 49 Biosurveillance 49 APCO Insight 49 EGIR 49 Afib 49 Symptom Checklist 49 Interoperability Standards 49 Fibromyalgia Syndrome 49 RH1 49 Rate ORR 49 Perforomist Inhalation Solution 49 phase IIb clinical 49 randomized controlled multicenter 49 Randomized Phase 49 Calorimetry 49 www.sematech.org 49 Toxicity Testing 49 Phase IIa trial 49 dose escalation phase 49 Framingham Offspring 49 PlatformOne 49 zotarolimus eluting stent 49 TRANSFORMS 49 Genetic Tests 49 NAEPP 49 SPECTRO 49 TechRankings 49 Cervical Dysplasia 49 ROTARIX 49 Cornea Donor Study 49 FDG PET imaging 49 MERIT ES 49 Paediatric Endocrinology 49 Reperfusion 49 MoxDuo IR 49 multicenter trials 49 Brief Intervention 49 Guidelines Issued 49 SBIR Contract 49 rEEG ® 49 Stent Coating 49 Childhood Asthma 49 prospective randomized placebo 49 NTx 49 HORIBA Medical 49 Phase 2a 49 IMPROVE HF 49 Teysuno 49 Outcome Measurement 49 PleuraFlow 49 epoetin alpha 49 AZILECT R 49 CERVARIX 49 DDW ® 49 VEITHsymposium 49 NIAP Common Criteria Evaluation 49 Interagency Appraisal 49 NARAC 49 Bexion 49 MedPredict 49 Medtronic CoreValve 49 Urgent Intervention Triage 49 microplasmin Phase III 49 Hematopathology 49 Gastric Ulcer 49 Biodegradable Polymers 49 demonstrated clinically meaningful 49 Functioning Scale 49 Microalbuminuria 49 dose cohort 49 QTinno TM 49 Dynamic Light Scattering 49 Sensory Integration 49 Conceptual Design 49 PLCO 49 HYVET 49 Novel Therapeutic 49 Erythropoiesis Stimulating Agents ESAs 49 ITAR Registration 49 Diagnostic Tool 49 Malware Detection 49 Hematological Cancers 49 Kinesis Survey 49 SRK Consulting SRK 49 Relationship Management System 49 Pharmacogenomic 49 phase III ACCLAIM 49 Glucosamine Chondroitin Arthritis 49 Metabolic Disease 49 Precision Positioning 49 randomized multicenter Phase III 49 Microdosing 49 Pharmacogenetic 49 ABCSG 49 Breast Exams 49 SUTIMCo 49 ILLUSTRATE 49 dose escalation trial 49 Metallurgical testwork 49 Study Shows Benefits 49 Undergo Mental 49 efalizumab 49 Patient Focused 49 nonrandomized 49 Structural Integrity 49 registrational Phase 49 Selection Criteria 49 Implementation Guides 49 Depressive Symptoms 49 Accessed #/#/# [001] 49 PRECISE 49 Left Ventricular 49 xTAG 49 ASTEROID 49 severe gastroparesis 49 Vasogen Celacade 49 Avantra Biosciences 49 MAGE A3 ASCI 49 EDEMA3 49 Prostate Cancer Outcomes 49 pharmacoeconomic analysis 49 Textile Fibers 49 NSABP 49 Successful Implementation 49 Dosimetry 49 DataDelta 49 onset AF 49 Prostate Cancer Symposium 49 COPERNICUS 49 HPTN 49 NCCTG N# 49 Improves Outcomes 49 Voluntary Consensus 49 Program NCEP 49 Multicentre 49 ICH GCP 49 GEM OS2 49 secondary efficacy endpoint 49 Fastpath 49 Interpersonal psychotherapy 49 zNose 49 Phase 1b 49 Phase III randomized controlled 49 Occupational Exposure 49 PREVENT IV 49 Pediatric Psychopharmacology 49 Mercury QuickTest Professional 49 carotid artery stenting CAS 49 PreDx DRS 49 HORIZONS AMI 49 Optasia Medical 49 XIENCE V Stent System 49 Revalidation 49 standard chemotherapy regimen 49 Stable Angina 49 TAXUS VI 49 EuroIntervention 49 Medidata Designer 49 factorial design 49 FLUPAN 49 Adverse Outcomes 49 Micromachining 49 Estrogen Receptor 49 AZILECT ® 49 TAXUS IV 49 Ischaemic 49 glucocorticoid induced osteoporosis 49 iChem ® VELOCITY 49 Raloxifene Evaluation MORE 49 Pharmacologic 49 sunitinib malate 49 EuroSCORE 49 Device Interoperability 49 TrialWorks 49 Qscan 49 prospectively randomized 49 Teriflunomide 49 multicenter multinational 49 PARTNER Trial 49 ELCAP 49 Radiation Induced 49 VitalHealth Software 48 Predictive Value 48 Preliminary Findings 48 BIBW 48 Betaferon ® 48 Acceptance Testing 48 placebo controlled dose escalation 48 Lung Flute 48 GHTF 48 electromagnetic flowmeter 48 placebo controlled studies 48 MelaFind R 48 myocardial viability 48 Rheos System 48 Nephros DSUs 48 Reaccreditation 48 ELONVA 48 GHG Inventory 48 CQI 48 Non inferiority 48 ABSORB clinical 48 Exploratory IND 48 REALITY Trial 48 Seasonal Influenza Vaccine 48 Related Mortality 48 SerDes transceivers 48 Study Shows Significant 48 Trandolapril 48 Nerve Stimulation 48 meta regression 48 DRDC Suffield 48 AutoStart 48 Immune Tolerance Network 48 Diabetes Interventions 48 Sibutramine Cardiovascular Outcomes 48 Self Efficacy 48 Logistic Regression 48 peg interferon 48 multicenter randomized 48 QIDS SR 48 pharmacokinetic pharmacodynamic PK PD 48 Solar Geophysical Activity 48 dosing cohorts 48 Phase 2b 48 adenoma recurrence 48 eSource 48 Myocardial Infarction 48 UL Environment 48 PROactive Study 48 MGN# 48 PosiRx 48 Process Improvement SCAMPI 48 PRADAXA 48 multicentre 48 clinical pharmacology studies 48 unblinding 48 Triage Stroke Panel 48 Medication Adherence 48 xTAG RVP 48 R3i 48 Quantitation 48 Liver Meeting 48 AACVPR 48 oral rivaroxaban 48 chemoradiation therapy 48 Cohort Study MACS 48 Test Detects 48 #F ML 48 PEMS 48 tolerability pharmacokinetics 48 Hospital Acquired Pneumonia 48 DfR Solutions 48 Oral Anticoagulants 48 J Immunol 48 Pluripotent Stem Cells 48 Pre RELAX AHF 48 Postoperative Pain 48 sirolimus eluting stents 48 prognostic variables 48 ritonavir boosted 48 Further Validates 48 NESARC 48 BioZ Dx 48 Implantable Cardioverter Defibrillator ICD 48 V3D Colon 48 prospective observational studies 48 Phase Forward InForm 48 Ozone Pollution 48 Phase IIb 48 Post hoc 48 Antimicrobial Susceptibility Testing 48 LSRO 48 recurrent glioma 48 unblind 48 Standard CMMI Appraisal 48 PDSS 48 Lipid Lowering Treatment 48 Nerve Regeneration 48 thorough QT 48 ER CHOP 48 unstable angina UA 48 Microfield EnergyConnect 48 SCD HeFT 48 SmartCycler 48 intracranial hypertension 48 Mirada Medical 48 DCCT 48 Meta Analyses 48 Photovoltaic Module 48 Adolescent Obesity 48 Intel ® QuickAssist 48 venous thromboembolic disease 48 FOLPI 48 OpenClinica Enterprise 48 BOLDER II 48 pertuzumab 48 VeriCall Edge 48 BEIR VII 48 pegylated interferon alfa 2b 48 Histopathologic 48 blind multicenter 48 Acute myocardial infarction 48 Mitigation Strategies 48 Hyphanox 48 Shows Promise Against 48 CaoSys 48 Behavioral Intervention 48 trials RCTs 48 RhuDex ® 48 Verbal Behavior 48 trastuzumab emtansine T DM1 48 FOREXYARD Daily Forex 48 Champion HERSHEY BEARS 48 EHR Adoption 48 BEXXAR Therapeutic Regimen 48 Orazol 48 Intervention Effectiveness CATIE 48 Total Hip Arthroplasty 48 Val HeFT 48 Panther Trak 48 double blinded randomized 48 #mg QD [002] 48 Cancer Biomarker 48 double blinded placebo 48 viral kinetics 48 immunohistochemical 48 CHEMSAS ® 48 IASLC 48 #-# Resource Estimate 48 Cardiogenic Shock 48 Retroscreen 48 Islet Transplantation 48 COMFORT II 48 Targeted Therapy 48 Common Criteria Testing 48 Congenital Heart Surgery 48 Custom NX DES 48 Phase IIa 48 ICAAC IDSA